{"gene":"SOCS2","run_date":"2026-06-10T07:46:37","timeline":{"discoveries":[{"year":1998,"finding":"SOCS2 (hSOCS-2) was identified as a binding partner of the activated insulin-like growth factor I receptor (IGF-IR) cytoplasmic domain via yeast two-hybrid screen and confirmed by GST-pulldown and co-immunoprecipitation in mammalian cells; interaction required kinase activity but not specific C-terminal tyrosines 950, 1250, 1251, or 1316.","method":"Yeast two-hybrid, GST-pulldown, reciprocal co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP confirmed in multiple assays, single lab","pmids":["9727029"],"is_preprint":false},{"year":1998,"finding":"SOCS1 and SOCS3, but not SOCS2, inhibit IFN-mediated tyrosine phosphorylation and nuclear translocation of STAT1, and block IFN-induced antiviral and antiproliferative activities in stable cell lines.","method":"Stable cell line overexpression, Western blot for STAT1 phosphorylation, antiviral/antiproliferative assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable cell lines with functional readouts, single lab, negative result for SOCS2 on IFN/STAT1 pathway","pmids":["9857039"],"is_preprint":false},{"year":1997,"finding":"SSI-2 (SOCS2) mRNA is induced by cytokine stimulation, and forced expression of SSI-2 in mouse myeloid leukemia M1 cells suppressed the apoptotic effect of LIF, similar to SSI-1.","method":"Northern blotting, forced expression/functional assay in M1 cells","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single functional assay, limited mechanistic detail","pmids":["9266833"],"is_preprint":false},{"year":2002,"finding":"SOCS2 overexpression in vivo (transgenic mice) results in enhanced growth rather than growth suppression, and SOCS2 protein binds endogenous GH receptors in multiple mouse organs; phosphopeptide binding studies identified phosphorylated tyrosine 595 on the GH receptor as the site of SOCS2 interaction.","method":"Transgenic mouse generation, co-immunoprecipitation with endogenous GHR, phosphopeptide binding assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo transgenic + biochemical binding mapping, replicated across multiple tissues","pmids":["12208853"],"is_preprint":false},{"year":2002,"finding":"The growth-enhancement phenotype of SOCS2-deficient mice is dependent on STAT5b; deletion of SOCS2 in mice also lacking STAT5b had little effect on growth, placing SOCS2 as a regulator upstream of STAT5b in the GH signaling pathway. Primary hepatocytes from SOCS2-/- mice show prolonged STAT5 phosphorylation in response to GH.","method":"Double-knockout mouse genetics (epistasis), primary hepatocyte GH signaling assay","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in vivo with mechanistic cellular readout, independently consistent with transgenic data","pmids":["12040024"],"is_preprint":false},{"year":2005,"finding":"SOCS2 negatively regulates GH signaling in vivo and in vitro; SOCS2-/- phenotype requires endogenous GH; SOCS2 binds two phosphorylated tyrosines on the GH receptor; mutagenesis showed both are essential for SOCS2 inhibitory function; the SOCS-box motif is essential for all inhibitory function.","method":"SOCS2-/- mice, exogenous GH treatment, structure/function mutagenesis, biochemical interaction studies","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis + KO mouse + biochemical interaction, multiple orthogonal methods","pmids":["15690087"],"is_preprint":false},{"year":2005,"finding":"SOCS2 promotes neurite outgrowth in CNS neurons and PC12 cells by binding to and constitutively phosphorylating the EGFR at Tyr845 (Src binding site), leading to inhibition of the neurite-inhibitory GTPase Rho and activation of Rac1; SOCS2-induced neurite outgrowth is blocked by EGFR inhibitors (PP3, AG490) or Src kinase inhibitor (PP2); overexpressed SHP-2 reduces constitutive EGFR phosphorylation and neurite outgrowth.","method":"Overexpression in neurons/PC12 cells, co-immunoprecipitation with EGFR, pharmacological inhibitors, GTPase activity assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP + pharmacological inhibition + functional readout, single lab","pmids":["14764607"],"is_preprint":false},{"year":2005,"finding":"SOCS2 can enhance IL-2- and IL-3-induced STAT phosphorylation and proliferation by promoting proteasome-dependent degradation of SOCS3 (and SOCS1); this requires an intact SOCS box and is enhanced by co-expression of elongin B/C, suggesting SOCS2 forms an E3 ligase complex that targets SOCS3 for degradation.","method":"Overexpression, proteasome inhibitor assays, co-expression with elongin B/C, Western blot for SOCS3 levels","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assay with mechanistic dissection, intact SOCS-box requirement shown, single lab","pmids":["16199887"],"is_preprint":false},{"year":2006,"finding":"Lipoxin A4 (LXA4) and aspirin-triggered lipoxin activate AhR and LXAR receptors in dendritic cells, triggering SOCS2 expression; SOCS2-deficient DCs are hyper-responsive to microbial stimuli and refractory to LXA4 inhibition (but not IL-10); in vivo, SOCS2-/- mice show uncontrolled cytokine production and elevated mortality upon infection.","method":"SOCS2-/- mouse model, DC stimulation assays, in vivo infection model","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse in vivo + ex vivo DC functional assays, multiple readouts, published in high-impact journal","pmids":["16415877"],"is_preprint":false},{"year":2006,"finding":"SOCS2 promotes prolactin-driven mammary alveolar morphogenesis; homozygous null mutation of Socs2 rescued the failure of lactation and reduced STAT5 phosphorylation in prolactin receptor heterozygous mice, demonstrating SOCS2 is a key negative regulator of the prolactin-signaling pathway in the mammary gland.","method":"Socs2-/- and PrlR+/- mouse genetics (epistasis), mammary gland transplantation, pSTAT5 measurement","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in vivo with molecular readout (pSTAT5), replicated mammary transplant model","pmids":["16469767"],"is_preprint":false},{"year":2006,"finding":"SOCS2 interacts with the leptin receptor at Y1077 (with higher binding affinity than CIS) and not at Y985; SOCS2 can block CIS interaction with Y985 through direct binding of SOCS2 to the CIS SOCS box, with elongin B/C recruitment crucial for suppressing CIS activity.","method":"MAPPIT two-hybrid in intact cells, binding affinity analysis, co-expression assays","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mammalian two-hybrid in intact cells with multiple binding site mappings, single lab","pmids":["16684815"],"is_preprint":false},{"year":2007,"finding":"Using MAPPIT, Y487 and Y595 were mapped as the major SOCS2 binding sites on the GH receptor (non-overlapping with STAT5 sites at Y534, Y566, Y627), ruling out SOCS2-mediated inhibition of STAT5 activation by competition for shared binding sites.","method":"MAPPIT mammalian two-hybrid, mutagenesis of GHR tyrosine residues","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based two-hybrid with systematic mutagenesis, single lab","pmids":["17666591"],"is_preprint":false},{"year":2008,"finding":"SOCS2 acts as an inhibitor of JAK2V617F-mediated signaling; SOCS2 knockdown induced constitutive STAT5 phosphorylation in JAK2V617F-expressing cells; cytokine independence in myeloproliferative disorder cell lines correlated with low SOCS2 expression, and CpG island hypermethylation of SOCS2 was identified in cytokine-independent cells.","method":"siRNA knockdown, STAT5 phosphorylation assay, CpG methylation analysis","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional KD with defined molecular readout, single lab","pmids":["18769447"],"is_preprint":false},{"year":2011,"finding":"SOCS2 is part of a multimeric complex with intrinsic ubiquitin ligase activity; SOCS2 directly ubiquitinates the GH receptor (GHR) and regulates cellular GHR levels in a proteasome-dependent manner; the SOCS-box interaction with Elongin B/C controls SOCS2 protein turnover; Y487 on GHR (not Y595) accounts for SOCS2-mediated GHR degradation; increased GHR levels are observed in SOCS2-/- mouse livers.","method":"Ubiquitin ligase activity assay, mutational analysis, SOCS2-/- mouse liver fractionation, proteasome inhibitor experiments","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro E3 ligase reconstitution + KO mouse + mutagenesis + proteasome inhibitor, multiple orthogonal methods","pmids":["21980433"],"is_preprint":false},{"year":2011,"finding":"SOCS2-/- CD4+ T cells show markedly enhanced Th2 differentiation; SOCS2-/- mice exhibit elevated IgE, eosinophilia, and type 2 responses after helminth antigen challenge; SOCS2-/- T cells show enhanced STAT6 and STAT5 phosphorylation but blunted STAT3 phosphorylation after T cell activation.","method":"SOCS2-/- mouse model, T cell differentiation assays, STAT phosphorylation Western blots, in vivo allergen/helminth challenge models","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse + in vivo challenge models + adoptive transfer + molecular readout, multiple orthogonal methods","pmids":["21646394"],"is_preprint":false},{"year":2011,"finding":"STAT5A-mediated SOCS2 expression is required for JAK2/STAT3 inhibition following c-Src inhibitor treatment in head and neck squamous carcinoma; inhibition of STAT5A (not STAT5B) reduces SOCS2 expression; SOCS2 inhibits JAK2 activity and JAK2-STAT3 binding; SOCS2 overexpression prevents STAT3 reactivation.","method":"siRNA knockdown, kinase assays, Western blotting, overexpression studies, in vivo heterotransplant model","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase assays + molecular pathway dissection with KD/OE, single lab","pmids":["22090359"],"is_preprint":false},{"year":2013,"finding":"SOCS2 associates with activated FLT3 through phosphotyrosine residues Y589 and Y919, co-localizes with FLT3 at the cell membrane, increases FLT3 ubiquitination, accelerates receptor degradation via proteasomes, and negatively regulates FLT3 signaling by blocking Erk1/2 and STAT5 activation; SOCS2 expression decreases FLT3-ITD-mediated cell proliferation.","method":"Co-immunoprecipitation, co-localization microscopy, ubiquitination assay, proliferation/colony formation assays","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP + ubiquitination assay + functional readouts, single lab","pmids":["23548639"],"is_preprint":false},{"year":2013,"finding":"SOCS2 expression is induced by androgens through a mechanism requiring STAT5 and androgen receptor-dependent transcription in prostate cancer cells; SOCS2 inhibits GH activation of JAK2, Src, and STAT5, and inhibits cell invasion and proliferation in vitro; in vivo, SOCS2 limits proliferation and IGF-1 production in the prostate in response to GH.","method":"Androgen treatment + STAT5/AR knockdown, kinase activity assays, invasion/proliferation assays, in vivo mouse prostate model","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection with KD and kinase assays + in vivo model, single lab","pmids":["24031028"],"is_preprint":false},{"year":2013,"finding":"SOCS2 is required for stable Foxp3 expression in inducible regulatory T cells (iTregs) in vitro and in vivo; SOCS2-deficient iTregs show elevated STAT6 phosphorylation upon IL-4 stimulation and secrete elevated IFN-γ and IL-13; SOCS2 maintains iTreg anti-inflammatory phenotype by downregulating IL-4 signaling.","method":"SOCS2-/- mouse, in vitro iTreg differentiation, in vivo OVA feeding model, cytokine measurement, STAT6 phosphorylation assay","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse + in vitro and in vivo assays + molecular readout, single lab","pmids":["23455506"],"is_preprint":false},{"year":2014,"finding":"SOCS2 biophysically reconstituted as part of the full-size CRL5(SOCS2) E3 ubiquitin ligase complex (SOCS2-ElonginBC-Cullin5-Rbx2); components pulled from human cell lysates using phosphorylated GHR peptide beads; complex is monomeric; affinities of protein-protein interactions within the complex measured by isothermal titration calorimetry.","method":"In vitro reconstitution, pulldown from cell lysates with phospho-GHR peptides, SEC-MALS, native MS, ITC","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of full complex + multiple biophysical methods in single rigorous study","pmids":["25505247"],"is_preprint":false},{"year":2016,"finding":"Tolerogenic nanoparticle-mediated induction of DC tolerogenic phenotype and Treg differentiation is mediated by AhR-dependent induction of SOCS2, which results in inhibition of NF-κB activation and proinflammatory cytokine production.","method":"Nanoparticle treatment, SOCS2 KO DCs, NF-κB activity assay, Treg differentiation assay in vivo","journal":"Science signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO DCs + in vivo mouse model + mechanistic pathway assay, single lab","pmids":["27330188"],"is_preprint":false},{"year":2017,"finding":"SOCS2 is the substrate recognition component of the E3 ubiquitin ligase responsible for ubiquitination and degradation of the GH receptor; a GHR variant P495T impairs SOCS2 binding (SOCS2 requires phosphorylated Tyr487 and Pro495/Thr494 residues for binding), resulting in decreased GHR internalization/degradation and prolonged GH signaling; NMR structural comparison confirmed the P495T substitution alters the SOCS2 binding site structure.","method":"TIRF microscopy, surface receptor expression measurement, mutagenesis, NMR spectroscopy, stable cell lines","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis + NMR structure + live imaging + functional signaling assays in single study","pmids":["28967904"],"is_preprint":false},{"year":2017,"finding":"SOCS2 (Cullin5-SOCS2 E3 ligase) targets the serine-threonine kinase NDR1/STK38 for K48-linked ubiquitination and proteasomal degradation; SOCS2 interacts with NDR1; SOCS2 overexpression antagonizes NDR1-induced TNFα-stimulated NF-κB activity; depletion of NDR1 rescues the effect of SOCS2-deficiency on TNFα-induced NF-κB transactivation; SOCS2-/- mice show pro-inflammatory phenotype correlating with elevated NDR1 and nuclear p65.","method":"Mass spectrometry proteomics upon SOCS2 depletion, co-immunoprecipitation, ubiquitination assay (K48-linkage), NF-κB reporter assay, SOCS2-/- colitis model","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — proteomic substrate screen + Co-IP + ubiquitination assay + KO mouse in vivo, multiple orthogonal methods","pmids":["28216640"],"is_preprint":false},{"year":2018,"finding":"METTL3-mediated N6-methyladenosine (m6A) modification of SOCS2 mRNA promotes SOCS2 mRNA degradation through the m6A reader protein YTHDF2; knockdown of METTL3 abolishes SOCS2 mRNA m6A modification and augments SOCS2 mRNA expression in HCC cells.","method":"m6A sequencing, meRIP-qPCR, METTL3 knockdown/CRISPR activation, YTHDF2 pathway analysis","journal":"Hepatology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — m6A-seq + meRIP-qPCR + CRISPR perturbation + multiple cell/animal models in single rigorous study","pmids":["29171881"],"is_preprint":false},{"year":2019,"finding":"Crystal structures of SOCS2-ElonginB-ElonginC in complex with phosphorylated peptides from GHR (pY595) and EpoR (pY426) solved at 1.98 Å and 2.69 Å; both peptides bind in extended conformation at the canonical SH2 pY binding site but capture different conformations of the EF loop via hydrophobic interactions; cancer-associated SNPs around the pY pocket weaken substrate-binding affinity.","method":"X-ray crystallography (co-crystal structures), biophysical binding affinity assays, cancer SNP mutagenesis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structures + biophysical validation + mutagenesis in single rigorous study","pmids":["31182716"],"is_preprint":false},{"year":2019,"finding":"KIAA0317 is an E3 ubiquitin ligase that degrades SOCS2 protein; KIAA0317-mediated SOCS2 degradation exacerbates inflammation in vitro; KIAA0317-knockout mice are resistant to LPS-induced pulmonary inflammation; a small molecule inhibitor of KIAA0317 (BC-1365) prevents SOCS2 degradation and attenuates LPS- and P. aeruginosa-induced lung inflammation in vivo.","method":"KIAA0317 KO mouse, siRNA knockdown, small molecule inhibitor, in vivo LPS/P. aeruginosa lung inflammation models","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse + pharmacological inhibitor + in vivo models + mechanistic pathway, multiple orthogonal approaches","pmids":["31578312"],"is_preprint":false},{"year":2021,"finding":"An exosite on the SOCS2-SH2 domain (opposite side from the pTyr-binding site) binds a non-phosphorylated peptide (F3) as an α-helix, stabilizing the SH2 domain and slowing dissociation of phosphorylated ligands, enhancing phosphopeptide binding affinity and increasing SOCS2 inhibition of GH signaling.","method":"Crystal structure of SOCS2/F3, biophysical binding assays (SPR/ITC), GH signaling functional assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure + biophysical assays + functional validation in single study","pmids":["34857742"],"is_preprint":false},{"year":2022,"finding":"SOCS2 promotes ferroptosis and radiosensitization in HCC by recognizing the N-terminal domain of SLC7A11 via the SOCS2 SH2 domain, and the L162/C166 residues of the SOCS2-BOX bind elongin B/C to form a SOCS2/elonginB/C complex that recruits ubiquitin and promotes K48-linked polyubiquitination degradation of SLC7A11.","method":"Co-immunoprecipitation, ubiquitination assay (K48-linked), domain mutagenesis, ferroptosis assays (lipid peroxidation, Fe2+, GPX4), in vivo xenograft","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — domain mutagenesis + ubiquitination assay + Co-IP + in vivo model + ferroptosis functional readouts","pmids":["35995846"],"is_preprint":false},{"year":2023,"finding":"Structure-based design targeting the SOCS2-SH2 domain Cys111 yielded a covalent inhibitor (MN551) and prodrug (MN714); co-crystal structure confirms covalent modification at Cys111; covalent engagement at Cys111 competitively blocks recruitment of SOCS2 to its native substrate; prodrug MN714 is cell-permeable and demasks in cells (confirmed by 19F NMR and cellular target engagement assay).","method":"Structure-based drug design, co-crystal structure, 19F NMR spectroscopy, cellular target engagement assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — co-crystal structure + in-cell NMR + cellular target engagement, rigorous single study","pmids":["37816714"],"is_preprint":false},{"year":2006,"finding":"SOCS2 overexpression in C2C12 cells inhibits spontaneous myotube formation and potentiates BMP-induced osteoblast differentiation by upregulating JunB protein through inhibition of JunB ubiquitin-proteasome degradation; SOCS2 reduces JunB ubiquitination in COS-7 cells; this effect does not require GH signaling.","method":"Stable transfection, proteasome inhibitor assay, ubiquitination assay, reporter gene assay","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay + functional differentiation assays + proteasome inhibitor, single lab","pmids":["16419040"],"is_preprint":false},{"year":2015,"finding":"SOCS2 deficiency unleashes HSC proliferation in vitro, sustaining STAT5 phosphorylation in response to IL-3, thrombopoietin, and GM-CSF; in vivo, SOCS2 deficiency leads to unrestricted myelopoietic response to 5-FU and exhaustion of long-term HSC function across serial bone marrow transplantations.","method":"Socs2-/- mouse, in vitro HSC assays, STAT5 phosphorylation, serial bone marrow transplantation","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse + in vitro STAT5 assay + serial transplantation, single lab","pmids":["25858143"],"is_preprint":false},{"year":2015,"finding":"SOCS2 balances hepatocyte proliferation during liver regeneration by preventing increases in GHR via ubiquitination and suppressing GH pathway activity during the first wave of proliferation; at later times, SOCS2 enhances hepatocyte proliferation by modulating a decrease in serum IGF-1 that allows GH release.","method":"SOCS2-/- mouse partial hepatectomy model, GHR ubiquitination assay, serum IGF-1 measurement, BrdU proliferation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with functional readout + ubiquitination evidence, single lab","pmids":["26703468"],"is_preprint":false},{"year":2009,"finding":"SOCS2 expression is dramatically upregulated during human monocyte-derived DC maturation; silencing SOCS2 inhibits DC maturation (reduced CD83, CD40, CD86, HLA-DR) and decreases LPS-induced activation of MAP kinases (SAPK/JNK, p38, ERK), IRF3, and NF-κB translocation, implicating SOCS2 in both MyD88-dependent and -independent TLR4 signaling pathways.","method":"siRNA knockdown, flow cytometry for DC maturation markers, Western blot for MAPK/IRF3/NF-κB","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD with multiple molecular readouts, single lab","pmids":["19779605"],"is_preprint":false},{"year":2019,"finding":"In human macrophages stimulated with indoxyl sulfate (IS), IS-activated AhR associates with the p65 NF-κB subunit causing mutual inhibition and early suppression of TNF-α; later, SOCS2 (directly induced by IS-activated AhR) relieves NF-κB repression, and ultimately AhR induces TNF-α by binding AhR binding sites in the TNF-α gene.","method":"AhR/NF-κB co-association assay, SOCS2 siRNA knockdown, chromatin binding assay, time-course TNF-α production in human macrophages","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD + binding assay + time-course mechanistic dissection, single lab","pmids":["31284759"],"is_preprint":false}],"current_model":"SOCS2 is a substrate-recognition subunit of the CRL5 (Cullin5-ElonginBC-RBX2) E3 ubiquitin ligase complex that binds phosphotyrosine-modified degrons on cytokine and growth factor receptors (GHR, EpoR, FLT3, IGF-1R, SLC7A11) via its SH2 domain, promoting their K48-linked ubiquitination and proteasomal degradation; it also targets non-receptor substrates including SOCS3, NDR1/STK38, and JunB for degradation, and its own expression is transcriptionally induced downstream of STAT5 (and AhR) and negatively regulated by METTL3/YTHDF2-mediated m6A mRNA modification; structurally, the SH2 domain engages pTyr residues in an extended conformation with an allosteric exosite, and the SOCS-box is essential for Elongin B/C interaction and all ubiquitin ligase function; physiologically, SOCS2-mediated GHR degradation limits GH/STAT5b-driven somatic growth, mammary development, and bone growth, while in immune cells SOCS2 restrains Th2 and iTreg responses, facilitates DC maturation via TLR4 signaling, and mediates lipoxin A4/AhR anti-inflammatory signaling; SOCS2 protein stability is itself regulated by the E3 ligase KIAA0317."},"narrative":{"mechanistic_narrative":"SOCS2 is the substrate-recognition subunit of a CRL5 (Cullin5–ElonginBC–Rbx2) E3 ubiquitin ligase that uses its SH2 domain to bind phosphotyrosine degrons on activated cytokine and growth-factor receptors and direct them for K48-linked ubiquitination and proteasomal degradation, thereby acting as a negative-feedback brake on growth-hormone and related signaling [PMID:25505247, PMID:21980433, PMID:28967904]. The complex was biophysically reconstituted as a monomeric SOCS2–ElonginBC–Cullin5–Rbx2 assembly that engages substrate via phosphorylated receptor peptides, and the SOCS-box motif that recruits Elongin B/C is essential for all of its inhibitory and ligase activity [PMID:25505247, PMID:15690087, PMID:21980433]. Structurally, the SH2 domain captures pTyr peptides from substrates such as GHR and EpoR in an extended conformation, with substrate-specific EF-loop conformations and an allosteric exosite that stabilizes the domain and tightens phosphopeptide binding [PMID:31182716, PMID:34857742]. Its principal physiological role is degradation of the growth hormone receptor at phospho-Tyr487, limiting GH/STAT5b-driven somatic and mammary growth — loss of SOCS2 elevates GHR and prolongs STAT5 signaling in a STAT5b-dependent manner [PMID:21980433, PMID:28967904, PMID:12040024, PMID:16469767]. SOCS2 extends this activity to additional receptors and non-receptor substrates, recognizing FLT3 and the cystine transporter SLC7A11 (promoting ferroptosis) for ubiquitin-dependent degradation, and targeting the kinase NDR1/STK38 and SOCS1/SOCS3 [PMID:23548639, PMID:35995846, PMID:28216640, PMID:16199887]. Its own abundance is tuned transcriptionally — induced downstream of STAT5 and AhR — post-transcriptionally by METTL3/YTHDF2-mediated m6A decay of its mRNA, and post-translationally by the E3 ligase KIAA0317 [PMID:22090359, PMID:29171881, PMID:31578312]. In immune cells SOCS2 acts as an anti-inflammatory regulator: it is induced by lipoxin A4/AhR signaling, restrains Th2 and iTreg responses and dendritic-cell inflammatory output, and limits NF-κB activation [PMID:16415877, PMID:21646394, PMID:23455506, PMID:28216640].","teleology":[{"year":1998,"claim":"Established SOCS2 as a physical partner of an activated growth-factor receptor, the first clue that it docks onto receptor signaling complexes.","evidence":"Yeast two-hybrid plus reciprocal Co-IP/GST-pulldown against the IGF-IR cytoplasmic domain","pmids":["9727029"],"confidence":"Medium","gaps":["Did not define the phosphotyrosine degron bound","No functional consequence of the interaction shown","Distinguished SOCS2 from SOCS1/SOCS3 only by binding, not mechanism"]},{"year":2002,"claim":"Resolved the paradox that SOCS2 enhances rather than suppresses growth and placed it as a GHR-binding negative regulator acting upstream of STAT5b.","evidence":"Transgenic and SOCS2/STAT5b double-knockout mouse genetics with GHR phosphopeptide binding mapping (pTyr595) and prolonged hepatocyte STAT5 phosphorylation","pmids":["12208853","12040024"],"confidence":"High","gaps":["Mechanism of GHR downregulation (degradation vs signaling block) not yet defined","Biphasic dose-dependent growth phenotype unexplained"]},{"year":2005,"claim":"Showed the SOCS-box is indispensable for inhibitory function and that SOCS2 can act through E3-ligase-type degradation of other SOCS proteins, foreshadowing its ligase identity.","evidence":"SOCS2-/- mice with exogenous GH, structure/function mutagenesis of GHR tyrosines and the SOCS-box, and proteasome/elongin BC-dependent SOCS3 degradation assays","pmids":["15690087","16199887"],"confidence":"Medium","gaps":["Direct demonstration of intrinsic ubiquitin ligase activity still lacking","Which substrates degraded in vivo unresolved"]},{"year":2006,"claim":"Expanded SOCS2 into immune and developmental physiology — anti-inflammatory control downstream of lipoxin A4/AhR and regulation of prolactin-driven mammary morphogenesis.","evidence":"SOCS2-/- mouse infection and DC stimulation models; Socs2/PrlR epistatic mouse crosses with pSTAT5 readouts; reports of non-GH JunB stabilization","pmids":["16415877","16469767","16419040"],"confidence":"High","gaps":["Whether immune phenotypes reflect receptor degradation or signaling competition not separated","Direct substrates in immune cells not identified at this stage"]},{"year":2011,"claim":"Demonstrated direct intrinsic ubiquitin ligase activity, establishing SOCS2 as an E3 that ubiquitinates GHR for proteasomal degradation and assigning distinct GHR tyrosines to binding vs degradation.","evidence":"In vitro ubiquitin ligase assays, mutational mapping (Tyr487 for degradation), SOCS2-/- liver GHR levels, proteasome inhibition; parallel T-cell knockout studies of Th2 control","pmids":["21980433","21646394"],"confidence":"High","gaps":["Full ligase complex composition and stoichiometry not yet defined","Substrate repertoire beyond GHR incomplete"]},{"year":2014,"claim":"Defined the molecular machine by reconstituting the full CRL5(SOCS2) complex and measuring its internal interaction affinities.","evidence":"In vitro reconstitution of SOCS2–ElonginBC–Cullin5–Rbx2, phospho-GHR peptide pulldown, SEC-MALS, native MS and ITC","pmids":["25505247"],"confidence":"High","gaps":["Did not provide atomic structure of substrate engagement","Catalytic cycle and neddylation dependence not addressed"]},{"year":2017,"claim":"Provided structural and disease-relevant detail of substrate recognition, linking a GHR variant that disrupts SOCS2 binding to impaired receptor degradation and prolonged GH signaling.","evidence":"NMR comparison of GHR P495T, TIRF/surface receptor imaging, mutagenesis; proteomic identification of NDR1/STK38 as a K48-ubiquitinated substrate with SOCS2-/- colitis model","pmids":["28967904","28216640"],"confidence":"High","gaps":["Whether GHR P495T causes a human growth phenotype not established here","Breadth of non-receptor substrate degron preferences unknown"]},{"year":2019,"claim":"Delivered atomic-resolution substrate recognition and revealed dual regulation of SOCS2 abundance by m6A mRNA decay and by a counteracting E3 ligase.","evidence":"Co-crystal structures of SOCS2-EloBC with GHR(pY595) and EpoR(pY426); METTL3/YTHDF2 m6A-seq/meRIP in HCC; KIAA0317 KO mice and inhibitor (BC-1365) in lung inflammation","pmids":["31182716","29171881","31578312"],"confidence":"High","gaps":["Structural basis for substrate selectivity beyond pY pocket only partially explained by EF-loop","Crosstalk between transcriptional, m6A, and proteostatic control not integrated"]},{"year":2022,"claim":"Extended SOCS2 substrate scope to the cystine transporter SLC7A11, coupling its ligase activity to ferroptosis and radiosensitization in cancer.","evidence":"Co-IP, domain mutagenesis (SH2 N-terminal recognition; SOCS-BOX L162/C166 for elongin BC), K48 ubiquitination assays, ferroptosis readouts and xenografts","pmids":["35995846"],"confidence":"High","gaps":["Generality of N-terminal (non-pTyr) substrate recognition unclear","In vivo contribution to tumor ferroptosis vs other pathways not isolated"]},{"year":2023,"claim":"Validated SOCS2 as a druggable target through structure-guided allosteric and covalent ligands that modulate phosphopeptide binding and block substrate recruitment.","evidence":"Crystal structure of an exosite-binding helical peptide enhancing binding; covalent Cys111 inhibitor MN551/prodrug MN714 with co-crystal, 19F NMR and cellular target engagement","pmids":["34857742","37816714"],"confidence":"High","gaps":["Endogenous ligand or physiological role of the exosite unknown","Cellular and in vivo efficacy of covalent inhibitors not established"]},{"year":null,"claim":"How the full substrate repertoire and degron rules of CRL5(SOCS2) are decoded in different tissues, and how its multilayer regulation is coordinated, remains open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unbiased proteome-wide degradation atlas across cell types","Integration of STAT5/AhR transcription, m6A decay, and KIAA0317 turnover into a quantitative regulatory model lacking","Whether reported non-degradative signaling roles (e.g., EGFR/Src in neurons) reflect a distinct mechanism unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[13,19,22,27]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[13,16,22,27]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,24]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,7,15]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[19,21,24]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[19,13]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[16,21]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[13,19,22,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,4,5,16]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,14,18,22]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[23]}],"complexes":["CRL5(SOCS2) (SOCS2–ElonginBC–Cullin5–Rbx2) E3 ubiquitin ligase"],"partners":["GHR","ELONGINB","ELONGINC","CUL5","FLT3","SLC7A11","STK38","IGF1R"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O14508","full_name":"Suppressor of cytokine signaling 2","aliases":["Cytokine-inducible SH2 protein 2","CIS-2","STAT-induced STAT inhibitor 2","SSI-2"],"length_aa":198,"mass_kda":22.2,"function":"Substrate-recognition component of a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex, also named CRL5 complex), which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as EPOR and GHR (PubMed:11781573, PubMed:21980433, PubMed:25505247, PubMed:31182716, PubMed:34857742). Specifically recognizes and binds phosphorylated proteins via its SH2 domain, promoting their ubiquitination (PubMed:21980433, PubMed:25505247, PubMed:31182716, PubMed:34857742, PubMed:37816714). The ECS(SOCS2) complex acts as a key regulator of growth hormone receptor (GHR) levels by mediating ubiquitination and degradation of GHR, following GHR phosphorylation by JAK2 (PubMed:21980433, PubMed:25505247, PubMed:34857742). The ECS(SOCS2) also catalyzes ubiquitination and degradation of JAK2-phosphorylated EPOR (PubMed:11781573)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/O14508/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SOCS2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SOCS2","total_profiled":1310},"omim":[{"mim_id":"617269","title":"SOCS2 ANTISENSE RNA 1, NONCODING; SOCS2AS1","url":"https://www.omim.org/entry/617269"},{"mim_id":"605117","title":"SUPPRESSOR OF CYTOKINE SIGNALING 2; SOCS2","url":"https://www.omim.org/entry/605117"},{"mim_id":"603597","title":"SUPPRESSOR OF CYTOKINE SIGNALING 1; SOCS1","url":"https://www.omim.org/entry/603597"},{"mim_id":"601407","title":"TYPE 2 DIABETES MELLITUS 2; T2D2","url":"https://www.omim.org/entry/601407"},{"mim_id":"600946","title":"GROWTH HORMONE RECEPTOR; GHR","url":"https://www.omim.org/entry/600946"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SOCS2"},"hgnc":{"alias_symbol":["STATI2","SSI2","SOCS-2","SSI-2","CIS2","Cish2"],"prev_symbol":[]},"alphafold":{"accession":"O14508","domains":[{"cath_id":"3.30.505.10","chopping":"32-140_147-158","consensus_level":"high","plddt":88.3168,"start":32,"end":158},{"cath_id":"1.10.750.20","chopping":"161-198","consensus_level":"medium","plddt":96.5389,"start":161,"end":198}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14508","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14508-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14508-F1-predicted_aligned_error_v6.png","plddt_mean":82.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SOCS2","jax_strain_url":"https://www.jax.org/strain/search?query=SOCS2"},"sequence":{"accession":"O14508","fasta_url":"https://rest.uniprot.org/uniprotkb/O14508.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14508/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14508"}},"corpus_meta":[{"pmid":"29171881","id":"PMC_29171881","title":"RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.","date":"2018","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/29171881","citation_count":1076,"is_preprint":false},{"pmid":"9857039","id":"PMC_9857039","title":"The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9857039","citation_count":327,"is_preprint":false},{"pmid":"35995846","id":"PMC_35995846","title":"SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma.","date":"2022","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/35995846","citation_count":267,"is_preprint":false},{"pmid":"16415877","id":"PMC_16415877","title":"Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent.","date":"2006","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16415877","citation_count":252,"is_preprint":false},{"pmid":"15690087","id":"PMC_15690087","title":"SOCS2 negatively regulates growth hormone action in vitro and in vivo.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15690087","citation_count":194,"is_preprint":false},{"pmid":"17070092","id":"PMC_17070092","title":"Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions.","date":"2006","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/17070092","citation_count":170,"is_preprint":false},{"pmid":"27330188","id":"PMC_27330188","title":"Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2.","date":"2016","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/27330188","citation_count":167,"is_preprint":false},{"pmid":"9727029","id":"PMC_9727029","title":"Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9727029","citation_count":166,"is_preprint":false},{"pmid":"9266833","id":"PMC_9266833","title":"Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9266833","citation_count":142,"is_preprint":false},{"pmid":"12208853","id":"PMC_12208853","title":"Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12208853","citation_count":138,"is_preprint":false},{"pmid":"12040024","id":"PMC_12040024","title":"Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b).","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12040024","citation_count":131,"is_preprint":false},{"pmid":"27342777","id":"PMC_27342777","title":"Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27342777","citation_count":127,"is_preprint":false},{"pmid":"16469767","id":"PMC_16469767","title":"Socs2 and elf5 mediate prolactin-induced mammary gland development.","date":"2006","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/16469767","citation_count":126,"is_preprint":false},{"pmid":"16199887","id":"PMC_16199887","title":"SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16199887","citation_count":122,"is_preprint":false},{"pmid":"10433229","id":"PMC_10433229","title":"Growth hormone regulation of SOCS-2, SOCS-3, and CIS messenger ribonucleic acid expression in the rat.","date":"1999","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10433229","citation_count":118,"is_preprint":false},{"pmid":"10630411","id":"PMC_10630411","title":"STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver.","date":"1999","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10630411","citation_count":100,"is_preprint":false},{"pmid":"28011622","id":"PMC_28011622","title":"MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28011622","citation_count":96,"is_preprint":false},{"pmid":"11401434","id":"PMC_11401434","title":"Lack of Socs2 expression causes the high-growth phenotype in mice.","date":"2001","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11401434","citation_count":93,"is_preprint":false},{"pmid":"32705223","id":"PMC_32705223","title":"m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/32705223","citation_count":92,"is_preprint":false},{"pmid":"26709655","id":"PMC_26709655","title":"SOCS2: physiological and pathological functions.","date":"2016","source":"Frontiers in bioscience (Elite edition)","url":"https://pubmed.ncbi.nlm.nih.gov/26709655","citation_count":80,"is_preprint":false},{"pmid":"37246269","id":"PMC_37246269","title":"Smoking-Induced M2-TAMs, via circEML4 in EVs, Promote the Progression of NSCLC through ALKBH5-Regulated m6A Modification of SOCS2 in NSCLC Cells.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37246269","citation_count":74,"is_preprint":false},{"pmid":"21646394","id":"PMC_21646394","title":"SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21646394","citation_count":71,"is_preprint":false},{"pmid":"16306139","id":"PMC_16306139","title":"Role of salicylic acid and fatty acid desaturation pathways in ssi2-mediated signaling.","date":"2005","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16306139","citation_count":69,"is_preprint":false},{"pmid":"33228663","id":"PMC_33228663","title":"LncRNA NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis.","date":"2020","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33228663","citation_count":68,"is_preprint":false},{"pmid":"14764607","id":"PMC_14764607","title":"SOCS2 induces neurite outgrowth by regulation of epidermal growth factor receptor activation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14764607","citation_count":68,"is_preprint":false},{"pmid":"22562833","id":"PMC_22562833","title":"SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high-fat-diet-fed mice.","date":"2012","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/22562833","citation_count":67,"is_preprint":false},{"pmid":"27038552","id":"PMC_27038552","title":"IL-8 induces miR-424-5p expression and modulates SOCS2/STAT5 signaling pathway in oral squamous cell carcinoma.","date":"2016","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27038552","citation_count":66,"is_preprint":false},{"pmid":"35864511","id":"PMC_35864511","title":"Engineered exosome-mediated delivery of circDIDO1 inhibits gastric cancer progression via regulation of MiR-1307-3p/SOCS2 Axis.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35864511","citation_count":64,"is_preprint":false},{"pmid":"21980433","id":"PMC_21980433","title":"The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21980433","citation_count":62,"is_preprint":false},{"pmid":"25561270","id":"PMC_25561270","title":"MiR-101 inhibits cell growth and tumorigenesis of Helicobacter pylori related gastric cancer by repression of SOCS2.","date":"2015","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25561270","citation_count":60,"is_preprint":false},{"pmid":"25025962","id":"PMC_25025962","title":"Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer.","date":"2014","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25025962","citation_count":59,"is_preprint":false},{"pmid":"30988277","id":"PMC_30988277","title":"MicroRNA-196a/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30988277","citation_count":59,"is_preprint":false},{"pmid":"22090359","id":"PMC_22090359","title":"STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22090359","citation_count":58,"is_preprint":false},{"pmid":"11279166","id":"PMC_11279166","title":"Insulin Induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 Skeletal Muscle Cells Is Mediated by Stat5*.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11279166","citation_count":54,"is_preprint":false},{"pmid":"24860421","id":"PMC_24860421","title":"Regulation of neurotrophin receptor (Trk) signaling: suppressor of cytokine signaling 2 (SOCS2) is a new player.","date":"2014","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24860421","citation_count":52,"is_preprint":false},{"pmid":"23548639","id":"PMC_23548639","title":"Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling.","date":"2013","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23548639","citation_count":52,"is_preprint":false},{"pmid":"16684815","id":"PMC_16684815","title":"A complex interaction pattern of CIS and SOCS2 with the leptin receptor.","date":"2006","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/16684815","citation_count":49,"is_preprint":false},{"pmid":"25858143","id":"PMC_25858143","title":"SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25858143","citation_count":48,"is_preprint":false},{"pmid":"32559839","id":"PMC_32559839","title":"Ling-gui-zhu-gan decoction alleviates hepatic steatosis through SOCS2 modification by N6-methyladenosine.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32559839","citation_count":47,"is_preprint":false},{"pmid":"31284759","id":"PMC_31284759","title":"Indoxyl sulfate-induced TNF-α is regulated by crosstalk between the aryl hydrocarbon receptor, NF-κB, and SOCS2 in human macrophages.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31284759","citation_count":47,"is_preprint":false},{"pmid":"33397365","id":"PMC_33397365","title":"CircNOL10 suppresses breast cancer progression by sponging miR-767-5p to regulate SOCS2/JAK/STAT signaling.","date":"2021","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/33397365","citation_count":45,"is_preprint":false},{"pmid":"11115404","id":"PMC_11115404","title":"Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling.","date":"2001","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11115404","citation_count":45,"is_preprint":false},{"pmid":"33002329","id":"PMC_33002329","title":"CircHivep2 contributes to microglia activation and inflammation via miR-181a-5p/SOCS2 signalling in mice with kainic acid-induced epileptic seizures.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33002329","citation_count":45,"is_preprint":false},{"pmid":"14601670","id":"PMC_14601670","title":"Restoration of defective cross talk in ssi2 mutants: role of salicylic acid, jasmonic acid, and fatty acids in SSI2-mediated signaling.","date":"2003","source":"Molecular plant-microbe interactions : MPMI","url":"https://pubmed.ncbi.nlm.nih.gov/14601670","citation_count":44,"is_preprint":false},{"pmid":"23455506","id":"PMC_23455506","title":"Regulation of Foxp3+ inducible regulatory T cell stability by SOCS2.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23455506","citation_count":44,"is_preprint":false},{"pmid":"32344463","id":"PMC_32344463","title":"MiR-3613-3p from carcinoma-associated fibroblasts exosomes promoted breast cancer cell proliferation and metastasis by regulating SOCS2 expression.","date":"2020","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/32344463","citation_count":43,"is_preprint":false},{"pmid":"34803490","id":"PMC_34803490","title":"SOCS2 Suppresses Inflammation and Apoptosis during NASH Progression through Limiting NF-κB Activation in Macrophages.","date":"2021","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34803490","citation_count":42,"is_preprint":false},{"pmid":"28967904","id":"PMC_28967904","title":"A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28967904","citation_count":41,"is_preprint":false},{"pmid":"23372669","id":"PMC_23372669","title":"t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23372669","citation_count":41,"is_preprint":false},{"pmid":"20367470","id":"PMC_20367470","title":"PAD4-dependent antibiosis contributes to the ssi2-conferred hyper-resistance to the green peach aphid.","date":"2010","source":"Molecular plant-microbe interactions : MPMI","url":"https://pubmed.ncbi.nlm.nih.gov/20367470","citation_count":40,"is_preprint":false},{"pmid":"27465557","id":"PMC_27465557","title":"The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27465557","citation_count":40,"is_preprint":false},{"pmid":"22795647","id":"PMC_22795647","title":"TLR8 and NOD signaling synergistically induce the production of IL-1β and IL-23 in monocyte-derived DCs and enhance the expression of the feedback inhibitor SOCS2.","date":"2012","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22795647","citation_count":40,"is_preprint":false},{"pmid":"24280133","id":"PMC_24280133","title":"SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.","date":"2014","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24280133","citation_count":39,"is_preprint":false},{"pmid":"16189149","id":"PMC_16189149","title":"Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma.","date":"2005","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16189149","citation_count":38,"is_preprint":false},{"pmid":"24031028","id":"PMC_24031028","title":"SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24031028","citation_count":38,"is_preprint":false},{"pmid":"25066769","id":"PMC_25066769","title":"β-Asarone (cis-2,4,5-trimethoxy-1-allyl phenyl), attenuates pro-inflammatory mediators by inhibiting NF-κB signaling and the JNK pathway in LPS activated BV-2 microglia cells.","date":"2014","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/25066769","citation_count":38,"is_preprint":false},{"pmid":"18769447","id":"PMC_18769447","title":"SOCS2: inhibitor of JAK2V617F-mediated signal transduction.","date":"2008","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18769447","citation_count":36,"is_preprint":false},{"pmid":"28216640","id":"PMC_28216640","title":"The ubiquitin ligase Cullin5SOCS2 regulates NDR1/STK38 stability and NF-κB transactivation.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28216640","citation_count":35,"is_preprint":false},{"pmid":"22886280","id":"PMC_22886280","title":"Inflammation and linear bone growth: the inhibitory role of SOCS2 on GH/IGF-1 signaling.","date":"2012","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/22886280","citation_count":35,"is_preprint":false},{"pmid":"30723477","id":"PMC_30723477","title":"SOCS2 Is Critical for the Balancing of Immune Response and Oxidate Stress Protecting Against Acetaminophen-Induced Acute Liver Injury.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30723477","citation_count":35,"is_preprint":false},{"pmid":"19779605","id":"PMC_19779605","title":"SOCS2 influences LPS induced human monocyte-derived dendritic cell maturation.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19779605","citation_count":35,"is_preprint":false},{"pmid":"16360125","id":"PMC_16360125","title":"Differential effects of SOCS2 on neuronal differentiation and morphology.","date":"2005","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/16360125","citation_count":35,"is_preprint":false},{"pmid":"33824269","id":"PMC_33824269","title":"The long-noncoding RNA SOCS2-AS1 suppresses endometrial cancer progression by regulating AURKA degradation.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33824269","citation_count":34,"is_preprint":false},{"pmid":"37816714","id":"PMC_37816714","title":"Structure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37816714","citation_count":33,"is_preprint":false},{"pmid":"32437330","id":"PMC_32437330","title":"LncRNA SOCS2-AS1 inhibits progression and metastasis of colorectal cancer through stabilizing SOCS2 and sponging miR-1264.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32437330","citation_count":32,"is_preprint":false},{"pmid":"38103096","id":"PMC_38103096","title":"Analysis of epigenetic clocks links yoga, sleep, education, reduced meat intake, coffee, and a SOCS2 gene variant to slower epigenetic aging.","date":"2023","source":"GeroScience","url":"https://pubmed.ncbi.nlm.nih.gov/38103096","citation_count":32,"is_preprint":false},{"pmid":"17666591","id":"PMC_17666591","title":"Mammalian protein-protein interaction trap (MAPPIT) analysis of STAT5, CIS, and SOCS2 interactions with the growth hormone receptor.","date":"2007","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/17666591","citation_count":32,"is_preprint":false},{"pmid":"15734145","id":"PMC_15734145","title":"Role of SOCS2 in growth hormone actions.","date":"2005","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/15734145","citation_count":31,"is_preprint":false},{"pmid":"26884939","id":"PMC_26884939","title":"miRNA-101 inhibits ovarian cancer cells proliferation and invasion by down-regulating expression of SOCS-2.","date":"2015","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26884939","citation_count":31,"is_preprint":false},{"pmid":"31182716","id":"PMC_31182716","title":"Structural insights into substrate recognition by the SOCS2 E3 ubiquitin ligase.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31182716","citation_count":30,"is_preprint":false},{"pmid":"35596790","id":"PMC_35596790","title":"RPL38 knockdown inhibits the inflammation and apoptosis in chondrocytes through regulating METTL3-mediated SOCS2 m6A modification in osteoarthritis.","date":"2022","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/35596790","citation_count":30,"is_preprint":false},{"pmid":"22228213","id":"PMC_22228213","title":"SOCS2 is the critical regulator of GH action in murine growth plate chondrogenesis.","date":"2012","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/22228213","citation_count":29,"is_preprint":false},{"pmid":"25505247","id":"PMC_25505247","title":"Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2).","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25505247","citation_count":28,"is_preprint":false},{"pmid":"38267746","id":"PMC_38267746","title":"POU6F1 promotes ferroptosis by increasing lncRNA-CASC2 transcription to regulate SOCS2/SLC7A11 signaling in gastric cancer.","date":"2024","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/38267746","citation_count":27,"is_preprint":false},{"pmid":"32536038","id":"PMC_32536038","title":"LncRNA WDFY3-AS2 suppresses proliferation and invasion in oesophageal squamous cell carcinoma by regulating miR-2355-5p/SOCS2 axis.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32536038","citation_count":26,"is_preprint":false},{"pmid":"15585682","id":"PMC_15585682","title":"Reduced bone mineral density in SOCS-2-deficient mice.","date":"2004","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/15585682","citation_count":26,"is_preprint":false},{"pmid":"20499047","id":"PMC_20499047","title":"The suppressor of cytokine signalling 2 (SOCS2) is a key repressor of insulin secretion.","date":"2010","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/20499047","citation_count":26,"is_preprint":false},{"pmid":"31816561","id":"PMC_31816561","title":"SOCS2 modulates adipose tissue inflammation and expansion in mice.","date":"2019","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31816561","citation_count":25,"is_preprint":false},{"pmid":"30779065","id":"PMC_30779065","title":"MiR-492 exerts tumor-promoting function in prostate cancer through repressing SOCS2 expression.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30779065","citation_count":25,"is_preprint":false},{"pmid":"27492125","id":"PMC_27492125","title":"Suppressor of cytokine signaling 2 (SOCS2) negatively regulates the expression of antimicrobial peptides by affecting the Stat transcriptional activity in shrimp Marsupenaeus japonicus.","date":"2016","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27492125","citation_count":24,"is_preprint":false},{"pmid":"28867579","id":"PMC_28867579","title":"SOCS2 exacerbates myocardial injury induced by ischemia/reperfusion in diabetic mice and H9c2 cells through inhibiting the JAK-STAT-IGF-1 pathway.","date":"2017","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28867579","citation_count":24,"is_preprint":false},{"pmid":"19340953","id":"PMC_19340953","title":"Suppressor of cytokine signaling 2 (SOCS-2) homologue in disk abalone: cloning, sequence characterization and expression analysis.","date":"2009","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19340953","citation_count":24,"is_preprint":false},{"pmid":"36539807","id":"PMC_36539807","title":"Increased expression of miR-194-5p through the circPVRL3/miR-194-5p/SOCS2 axis promotes proliferation and metastasis in pancreatic ductal adenocarcinoma by activating the PI3K/AKT signaling pathway.","date":"2022","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/36539807","citation_count":23,"is_preprint":false},{"pmid":"26703468","id":"PMC_26703468","title":"SOCS2 Balances Metabolic and Restorative Requirements during Liver Regeneration.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26703468","citation_count":22,"is_preprint":false},{"pmid":"36119773","id":"PMC_36119773","title":"Hepatocellular carcinoma-derived exosomal miRNA-761 regulates the tumor microenvironment by targeting the SOCS2/JAK2/STAT3 pathway.","date":"2022","source":"World journal of emergency medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36119773","citation_count":22,"is_preprint":false},{"pmid":"34054537","id":"PMC_34054537","title":"CircRNA circ_0006677 Inhibits the Progression and Glycolysis in Non-Small-Cell Lung Cancer by Sponging miR-578 and Regulating SOCS2 Expression.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34054537","citation_count":21,"is_preprint":false},{"pmid":"34857742","id":"PMC_34857742","title":"Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34857742","citation_count":20,"is_preprint":false},{"pmid":"16419040","id":"PMC_16419040","title":"SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16419040","citation_count":20,"is_preprint":false},{"pmid":"10807178","id":"PMC_10807178","title":"Synthesis and biological evaluation of integrin antagonists containing trans- and cis-2,5-disubstituted THF rings.","date":"2000","source":"Chemistry (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/10807178","citation_count":20,"is_preprint":false},{"pmid":"19008912","id":"PMC_19008912","title":"Insulin regulates SOCS2 expression and the mitogenic effect of IGF-1 in mesangial cells.","date":"2008","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/19008912","citation_count":19,"is_preprint":false},{"pmid":"31949423","id":"PMC_31949423","title":"Role of SOCS2 in the Regulation of Immune Response and Development of the Experimental Autoimmune Encephalomyelitis.","date":"2019","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/31949423","citation_count":19,"is_preprint":false},{"pmid":"31578312","id":"PMC_31578312","title":"KIAA0317 regulates pulmonary inflammation through SOCS2 degradation.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31578312","citation_count":18,"is_preprint":false},{"pmid":"36455458","id":"PMC_36455458","title":"SOCS2 protects against chemical-induced hepatocellular carcinoma progression by modulating inflammation and cell proliferation in the liver.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36455458","citation_count":18,"is_preprint":false},{"pmid":"38084702","id":"PMC_38084702","title":"CTRP6 protects against ferroptosis to drive lung cancer progression and metastasis by destabilizing SOCS2 and augmenting the xCT/GPX4 pathway.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38084702","citation_count":17,"is_preprint":false},{"pmid":"35730258","id":"PMC_35730258","title":"Upregulation of miR-144-3p alleviates Doxorubicin-induced heart failure and cardiomyocytes apoptosis via SOCS2/PI3K/AKT axis.","date":"2022","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/35730258","citation_count":17,"is_preprint":false},{"pmid":"39409145","id":"PMC_39409145","title":"Leveraging Therapeutic Proteins and Peptides from Lumbricus Earthworms: Targeting SOCS2 E3 Ligase for Cardiovascular Therapy through Molecular Dynamics Simulations.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39409145","citation_count":17,"is_preprint":false},{"pmid":"29207635","id":"PMC_29207635","title":"SOCS2 overexpression alleviates diabetic nephropathy in rats by inhibiting the TLR4/NF-κB pathway.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29207635","citation_count":17,"is_preprint":false},{"pmid":"31298374","id":"PMC_31298374","title":"MiR-875 can regulate the proliferation and apoptosis of non-small cell lung cancer cells via targeting SOCS2.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31298374","citation_count":17,"is_preprint":false},{"pmid":"32733634","id":"PMC_32733634","title":"SOCS2 Inhibits Mitochondrial Fatty Acid Oxidation via Suppressing LepR/JAK2/AMPK Signaling Pathway in Mouse Adipocytes.","date":"2020","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/32733634","citation_count":16,"is_preprint":false},{"pmid":"33777211","id":"PMC_33777211","title":"Upregulation of circ-ASPH contributes to glioma cell proliferation and aggressiveness by targeting the miR-599/AR/SOCS2-AS1 signaling pathway.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33777211","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54252,"output_tokens":8546,"usd":0.145473,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18162,"output_tokens":4240,"usd":0.098405,"stage2_stop_reason":"end_turn"},"total_usd":0.243878,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"SOCS2 (hSOCS-2) was identified as a binding partner of the activated insulin-like growth factor I receptor (IGF-IR) cytoplasmic domain via yeast two-hybrid screen and confirmed by GST-pulldown and co-immunoprecipitation in mammalian cells; interaction required kinase activity but not specific C-terminal tyrosines 950, 1250, 1251, or 1316.\",\n      \"method\": \"Yeast two-hybrid, GST-pulldown, reciprocal co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP confirmed in multiple assays, single lab\",\n      \"pmids\": [\"9727029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SOCS1 and SOCS3, but not SOCS2, inhibit IFN-mediated tyrosine phosphorylation and nuclear translocation of STAT1, and block IFN-induced antiviral and antiproliferative activities in stable cell lines.\",\n      \"method\": \"Stable cell line overexpression, Western blot for STAT1 phosphorylation, antiviral/antiproliferative assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable cell lines with functional readouts, single lab, negative result for SOCS2 on IFN/STAT1 pathway\",\n      \"pmids\": [\"9857039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"SSI-2 (SOCS2) mRNA is induced by cytokine stimulation, and forced expression of SSI-2 in mouse myeloid leukemia M1 cells suppressed the apoptotic effect of LIF, similar to SSI-1.\",\n      \"method\": \"Northern blotting, forced expression/functional assay in M1 cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single functional assay, limited mechanistic detail\",\n      \"pmids\": [\"9266833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"SOCS2 overexpression in vivo (transgenic mice) results in enhanced growth rather than growth suppression, and SOCS2 protein binds endogenous GH receptors in multiple mouse organs; phosphopeptide binding studies identified phosphorylated tyrosine 595 on the GH receptor as the site of SOCS2 interaction.\",\n      \"method\": \"Transgenic mouse generation, co-immunoprecipitation with endogenous GHR, phosphopeptide binding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo transgenic + biochemical binding mapping, replicated across multiple tissues\",\n      \"pmids\": [\"12208853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The growth-enhancement phenotype of SOCS2-deficient mice is dependent on STAT5b; deletion of SOCS2 in mice also lacking STAT5b had little effect on growth, placing SOCS2 as a regulator upstream of STAT5b in the GH signaling pathway. Primary hepatocytes from SOCS2-/- mice show prolonged STAT5 phosphorylation in response to GH.\",\n      \"method\": \"Double-knockout mouse genetics (epistasis), primary hepatocyte GH signaling assay\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in vivo with mechanistic cellular readout, independently consistent with transgenic data\",\n      \"pmids\": [\"12040024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"SOCS2 negatively regulates GH signaling in vivo and in vitro; SOCS2-/- phenotype requires endogenous GH; SOCS2 binds two phosphorylated tyrosines on the GH receptor; mutagenesis showed both are essential for SOCS2 inhibitory function; the SOCS-box motif is essential for all inhibitory function.\",\n      \"method\": \"SOCS2-/- mice, exogenous GH treatment, structure/function mutagenesis, biochemical interaction studies\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis + KO mouse + biochemical interaction, multiple orthogonal methods\",\n      \"pmids\": [\"15690087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"SOCS2 promotes neurite outgrowth in CNS neurons and PC12 cells by binding to and constitutively phosphorylating the EGFR at Tyr845 (Src binding site), leading to inhibition of the neurite-inhibitory GTPase Rho and activation of Rac1; SOCS2-induced neurite outgrowth is blocked by EGFR inhibitors (PP3, AG490) or Src kinase inhibitor (PP2); overexpressed SHP-2 reduces constitutive EGFR phosphorylation and neurite outgrowth.\",\n      \"method\": \"Overexpression in neurons/PC12 cells, co-immunoprecipitation with EGFR, pharmacological inhibitors, GTPase activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP + pharmacological inhibition + functional readout, single lab\",\n      \"pmids\": [\"14764607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"SOCS2 can enhance IL-2- and IL-3-induced STAT phosphorylation and proliferation by promoting proteasome-dependent degradation of SOCS3 (and SOCS1); this requires an intact SOCS box and is enhanced by co-expression of elongin B/C, suggesting SOCS2 forms an E3 ligase complex that targets SOCS3 for degradation.\",\n      \"method\": \"Overexpression, proteasome inhibitor assays, co-expression with elongin B/C, Western blot for SOCS3 levels\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assay with mechanistic dissection, intact SOCS-box requirement shown, single lab\",\n      \"pmids\": [\"16199887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Lipoxin A4 (LXA4) and aspirin-triggered lipoxin activate AhR and LXAR receptors in dendritic cells, triggering SOCS2 expression; SOCS2-deficient DCs are hyper-responsive to microbial stimuli and refractory to LXA4 inhibition (but not IL-10); in vivo, SOCS2-/- mice show uncontrolled cytokine production and elevated mortality upon infection.\",\n      \"method\": \"SOCS2-/- mouse model, DC stimulation assays, in vivo infection model\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse in vivo + ex vivo DC functional assays, multiple readouts, published in high-impact journal\",\n      \"pmids\": [\"16415877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SOCS2 promotes prolactin-driven mammary alveolar morphogenesis; homozygous null mutation of Socs2 rescued the failure of lactation and reduced STAT5 phosphorylation in prolactin receptor heterozygous mice, demonstrating SOCS2 is a key negative regulator of the prolactin-signaling pathway in the mammary gland.\",\n      \"method\": \"Socs2-/- and PrlR+/- mouse genetics (epistasis), mammary gland transplantation, pSTAT5 measurement\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in vivo with molecular readout (pSTAT5), replicated mammary transplant model\",\n      \"pmids\": [\"16469767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SOCS2 interacts with the leptin receptor at Y1077 (with higher binding affinity than CIS) and not at Y985; SOCS2 can block CIS interaction with Y985 through direct binding of SOCS2 to the CIS SOCS box, with elongin B/C recruitment crucial for suppressing CIS activity.\",\n      \"method\": \"MAPPIT two-hybrid in intact cells, binding affinity analysis, co-expression assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mammalian two-hybrid in intact cells with multiple binding site mappings, single lab\",\n      \"pmids\": [\"16684815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Using MAPPIT, Y487 and Y595 were mapped as the major SOCS2 binding sites on the GH receptor (non-overlapping with STAT5 sites at Y534, Y566, Y627), ruling out SOCS2-mediated inhibition of STAT5 activation by competition for shared binding sites.\",\n      \"method\": \"MAPPIT mammalian two-hybrid, mutagenesis of GHR tyrosine residues\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based two-hybrid with systematic mutagenesis, single lab\",\n      \"pmids\": [\"17666591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SOCS2 acts as an inhibitor of JAK2V617F-mediated signaling; SOCS2 knockdown induced constitutive STAT5 phosphorylation in JAK2V617F-expressing cells; cytokine independence in myeloproliferative disorder cell lines correlated with low SOCS2 expression, and CpG island hypermethylation of SOCS2 was identified in cytokine-independent cells.\",\n      \"method\": \"siRNA knockdown, STAT5 phosphorylation assay, CpG methylation analysis\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional KD with defined molecular readout, single lab\",\n      \"pmids\": [\"18769447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SOCS2 is part of a multimeric complex with intrinsic ubiquitin ligase activity; SOCS2 directly ubiquitinates the GH receptor (GHR) and regulates cellular GHR levels in a proteasome-dependent manner; the SOCS-box interaction with Elongin B/C controls SOCS2 protein turnover; Y487 on GHR (not Y595) accounts for SOCS2-mediated GHR degradation; increased GHR levels are observed in SOCS2-/- mouse livers.\",\n      \"method\": \"Ubiquitin ligase activity assay, mutational analysis, SOCS2-/- mouse liver fractionation, proteasome inhibitor experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro E3 ligase reconstitution + KO mouse + mutagenesis + proteasome inhibitor, multiple orthogonal methods\",\n      \"pmids\": [\"21980433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SOCS2-/- CD4+ T cells show markedly enhanced Th2 differentiation; SOCS2-/- mice exhibit elevated IgE, eosinophilia, and type 2 responses after helminth antigen challenge; SOCS2-/- T cells show enhanced STAT6 and STAT5 phosphorylation but blunted STAT3 phosphorylation after T cell activation.\",\n      \"method\": \"SOCS2-/- mouse model, T cell differentiation assays, STAT phosphorylation Western blots, in vivo allergen/helminth challenge models\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse + in vivo challenge models + adoptive transfer + molecular readout, multiple orthogonal methods\",\n      \"pmids\": [\"21646394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"STAT5A-mediated SOCS2 expression is required for JAK2/STAT3 inhibition following c-Src inhibitor treatment in head and neck squamous carcinoma; inhibition of STAT5A (not STAT5B) reduces SOCS2 expression; SOCS2 inhibits JAK2 activity and JAK2-STAT3 binding; SOCS2 overexpression prevents STAT3 reactivation.\",\n      \"method\": \"siRNA knockdown, kinase assays, Western blotting, overexpression studies, in vivo heterotransplant model\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase assays + molecular pathway dissection with KD/OE, single lab\",\n      \"pmids\": [\"22090359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOCS2 associates with activated FLT3 through phosphotyrosine residues Y589 and Y919, co-localizes with FLT3 at the cell membrane, increases FLT3 ubiquitination, accelerates receptor degradation via proteasomes, and negatively regulates FLT3 signaling by blocking Erk1/2 and STAT5 activation; SOCS2 expression decreases FLT3-ITD-mediated cell proliferation.\",\n      \"method\": \"Co-immunoprecipitation, co-localization microscopy, ubiquitination assay, proliferation/colony formation assays\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP + ubiquitination assay + functional readouts, single lab\",\n      \"pmids\": [\"23548639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOCS2 expression is induced by androgens through a mechanism requiring STAT5 and androgen receptor-dependent transcription in prostate cancer cells; SOCS2 inhibits GH activation of JAK2, Src, and STAT5, and inhibits cell invasion and proliferation in vitro; in vivo, SOCS2 limits proliferation and IGF-1 production in the prostate in response to GH.\",\n      \"method\": \"Androgen treatment + STAT5/AR knockdown, kinase activity assays, invasion/proliferation assays, in vivo mouse prostate model\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection with KD and kinase assays + in vivo model, single lab\",\n      \"pmids\": [\"24031028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOCS2 is required for stable Foxp3 expression in inducible regulatory T cells (iTregs) in vitro and in vivo; SOCS2-deficient iTregs show elevated STAT6 phosphorylation upon IL-4 stimulation and secrete elevated IFN-γ and IL-13; SOCS2 maintains iTreg anti-inflammatory phenotype by downregulating IL-4 signaling.\",\n      \"method\": \"SOCS2-/- mouse, in vitro iTreg differentiation, in vivo OVA feeding model, cytokine measurement, STAT6 phosphorylation assay\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse + in vitro and in vivo assays + molecular readout, single lab\",\n      \"pmids\": [\"23455506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOCS2 biophysically reconstituted as part of the full-size CRL5(SOCS2) E3 ubiquitin ligase complex (SOCS2-ElonginBC-Cullin5-Rbx2); components pulled from human cell lysates using phosphorylated GHR peptide beads; complex is monomeric; affinities of protein-protein interactions within the complex measured by isothermal titration calorimetry.\",\n      \"method\": \"In vitro reconstitution, pulldown from cell lysates with phospho-GHR peptides, SEC-MALS, native MS, ITC\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of full complex + multiple biophysical methods in single rigorous study\",\n      \"pmids\": [\"25505247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Tolerogenic nanoparticle-mediated induction of DC tolerogenic phenotype and Treg differentiation is mediated by AhR-dependent induction of SOCS2, which results in inhibition of NF-κB activation and proinflammatory cytokine production.\",\n      \"method\": \"Nanoparticle treatment, SOCS2 KO DCs, NF-κB activity assay, Treg differentiation assay in vivo\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO DCs + in vivo mouse model + mechanistic pathway assay, single lab\",\n      \"pmids\": [\"27330188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOCS2 is the substrate recognition component of the E3 ubiquitin ligase responsible for ubiquitination and degradation of the GH receptor; a GHR variant P495T impairs SOCS2 binding (SOCS2 requires phosphorylated Tyr487 and Pro495/Thr494 residues for binding), resulting in decreased GHR internalization/degradation and prolonged GH signaling; NMR structural comparison confirmed the P495T substitution alters the SOCS2 binding site structure.\",\n      \"method\": \"TIRF microscopy, surface receptor expression measurement, mutagenesis, NMR spectroscopy, stable cell lines\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis + NMR structure + live imaging + functional signaling assays in single study\",\n      \"pmids\": [\"28967904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOCS2 (Cullin5-SOCS2 E3 ligase) targets the serine-threonine kinase NDR1/STK38 for K48-linked ubiquitination and proteasomal degradation; SOCS2 interacts with NDR1; SOCS2 overexpression antagonizes NDR1-induced TNFα-stimulated NF-κB activity; depletion of NDR1 rescues the effect of SOCS2-deficiency on TNFα-induced NF-κB transactivation; SOCS2-/- mice show pro-inflammatory phenotype correlating with elevated NDR1 and nuclear p65.\",\n      \"method\": \"Mass spectrometry proteomics upon SOCS2 depletion, co-immunoprecipitation, ubiquitination assay (K48-linkage), NF-κB reporter assay, SOCS2-/- colitis model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — proteomic substrate screen + Co-IP + ubiquitination assay + KO mouse in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"28216640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"METTL3-mediated N6-methyladenosine (m6A) modification of SOCS2 mRNA promotes SOCS2 mRNA degradation through the m6A reader protein YTHDF2; knockdown of METTL3 abolishes SOCS2 mRNA m6A modification and augments SOCS2 mRNA expression in HCC cells.\",\n      \"method\": \"m6A sequencing, meRIP-qPCR, METTL3 knockdown/CRISPR activation, YTHDF2 pathway analysis\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — m6A-seq + meRIP-qPCR + CRISPR perturbation + multiple cell/animal models in single rigorous study\",\n      \"pmids\": [\"29171881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structures of SOCS2-ElonginB-ElonginC in complex with phosphorylated peptides from GHR (pY595) and EpoR (pY426) solved at 1.98 Å and 2.69 Å; both peptides bind in extended conformation at the canonical SH2 pY binding site but capture different conformations of the EF loop via hydrophobic interactions; cancer-associated SNPs around the pY pocket weaken substrate-binding affinity.\",\n      \"method\": \"X-ray crystallography (co-crystal structures), biophysical binding affinity assays, cancer SNP mutagenesis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structures + biophysical validation + mutagenesis in single rigorous study\",\n      \"pmids\": [\"31182716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KIAA0317 is an E3 ubiquitin ligase that degrades SOCS2 protein; KIAA0317-mediated SOCS2 degradation exacerbates inflammation in vitro; KIAA0317-knockout mice are resistant to LPS-induced pulmonary inflammation; a small molecule inhibitor of KIAA0317 (BC-1365) prevents SOCS2 degradation and attenuates LPS- and P. aeruginosa-induced lung inflammation in vivo.\",\n      \"method\": \"KIAA0317 KO mouse, siRNA knockdown, small molecule inhibitor, in vivo LPS/P. aeruginosa lung inflammation models\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse + pharmacological inhibitor + in vivo models + mechanistic pathway, multiple orthogonal approaches\",\n      \"pmids\": [\"31578312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"An exosite on the SOCS2-SH2 domain (opposite side from the pTyr-binding site) binds a non-phosphorylated peptide (F3) as an α-helix, stabilizing the SH2 domain and slowing dissociation of phosphorylated ligands, enhancing phosphopeptide binding affinity and increasing SOCS2 inhibition of GH signaling.\",\n      \"method\": \"Crystal structure of SOCS2/F3, biophysical binding assays (SPR/ITC), GH signaling functional assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure + biophysical assays + functional validation in single study\",\n      \"pmids\": [\"34857742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SOCS2 promotes ferroptosis and radiosensitization in HCC by recognizing the N-terminal domain of SLC7A11 via the SOCS2 SH2 domain, and the L162/C166 residues of the SOCS2-BOX bind elongin B/C to form a SOCS2/elonginB/C complex that recruits ubiquitin and promotes K48-linked polyubiquitination degradation of SLC7A11.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay (K48-linked), domain mutagenesis, ferroptosis assays (lipid peroxidation, Fe2+, GPX4), in vivo xenograft\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — domain mutagenesis + ubiquitination assay + Co-IP + in vivo model + ferroptosis functional readouts\",\n      \"pmids\": [\"35995846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Structure-based design targeting the SOCS2-SH2 domain Cys111 yielded a covalent inhibitor (MN551) and prodrug (MN714); co-crystal structure confirms covalent modification at Cys111; covalent engagement at Cys111 competitively blocks recruitment of SOCS2 to its native substrate; prodrug MN714 is cell-permeable and demasks in cells (confirmed by 19F NMR and cellular target engagement assay).\",\n      \"method\": \"Structure-based drug design, co-crystal structure, 19F NMR spectroscopy, cellular target engagement assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — co-crystal structure + in-cell NMR + cellular target engagement, rigorous single study\",\n      \"pmids\": [\"37816714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SOCS2 overexpression in C2C12 cells inhibits spontaneous myotube formation and potentiates BMP-induced osteoblast differentiation by upregulating JunB protein through inhibition of JunB ubiquitin-proteasome degradation; SOCS2 reduces JunB ubiquitination in COS-7 cells; this effect does not require GH signaling.\",\n      \"method\": \"Stable transfection, proteasome inhibitor assay, ubiquitination assay, reporter gene assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay + functional differentiation assays + proteasome inhibitor, single lab\",\n      \"pmids\": [\"16419040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SOCS2 deficiency unleashes HSC proliferation in vitro, sustaining STAT5 phosphorylation in response to IL-3, thrombopoietin, and GM-CSF; in vivo, SOCS2 deficiency leads to unrestricted myelopoietic response to 5-FU and exhaustion of long-term HSC function across serial bone marrow transplantations.\",\n      \"method\": \"Socs2-/- mouse, in vitro HSC assays, STAT5 phosphorylation, serial bone marrow transplantation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse + in vitro STAT5 assay + serial transplantation, single lab\",\n      \"pmids\": [\"25858143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SOCS2 balances hepatocyte proliferation during liver regeneration by preventing increases in GHR via ubiquitination and suppressing GH pathway activity during the first wave of proliferation; at later times, SOCS2 enhances hepatocyte proliferation by modulating a decrease in serum IGF-1 that allows GH release.\",\n      \"method\": \"SOCS2-/- mouse partial hepatectomy model, GHR ubiquitination assay, serum IGF-1 measurement, BrdU proliferation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with functional readout + ubiquitination evidence, single lab\",\n      \"pmids\": [\"26703468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SOCS2 expression is dramatically upregulated during human monocyte-derived DC maturation; silencing SOCS2 inhibits DC maturation (reduced CD83, CD40, CD86, HLA-DR) and decreases LPS-induced activation of MAP kinases (SAPK/JNK, p38, ERK), IRF3, and NF-κB translocation, implicating SOCS2 in both MyD88-dependent and -independent TLR4 signaling pathways.\",\n      \"method\": \"siRNA knockdown, flow cytometry for DC maturation markers, Western blot for MAPK/IRF3/NF-κB\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD with multiple molecular readouts, single lab\",\n      \"pmids\": [\"19779605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In human macrophages stimulated with indoxyl sulfate (IS), IS-activated AhR associates with the p65 NF-κB subunit causing mutual inhibition and early suppression of TNF-α; later, SOCS2 (directly induced by IS-activated AhR) relieves NF-κB repression, and ultimately AhR induces TNF-α by binding AhR binding sites in the TNF-α gene.\",\n      \"method\": \"AhR/NF-κB co-association assay, SOCS2 siRNA knockdown, chromatin binding assay, time-course TNF-α production in human macrophages\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD + binding assay + time-course mechanistic dissection, single lab\",\n      \"pmids\": [\"31284759\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SOCS2 is a substrate-recognition subunit of the CRL5 (Cullin5-ElonginBC-RBX2) E3 ubiquitin ligase complex that binds phosphotyrosine-modified degrons on cytokine and growth factor receptors (GHR, EpoR, FLT3, IGF-1R, SLC7A11) via its SH2 domain, promoting their K48-linked ubiquitination and proteasomal degradation; it also targets non-receptor substrates including SOCS3, NDR1/STK38, and JunB for degradation, and its own expression is transcriptionally induced downstream of STAT5 (and AhR) and negatively regulated by METTL3/YTHDF2-mediated m6A mRNA modification; structurally, the SH2 domain engages pTyr residues in an extended conformation with an allosteric exosite, and the SOCS-box is essential for Elongin B/C interaction and all ubiquitin ligase function; physiologically, SOCS2-mediated GHR degradation limits GH/STAT5b-driven somatic growth, mammary development, and bone growth, while in immune cells SOCS2 restrains Th2 and iTreg responses, facilitates DC maturation via TLR4 signaling, and mediates lipoxin A4/AhR anti-inflammatory signaling; SOCS2 protein stability is itself regulated by the E3 ligase KIAA0317.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SOCS2 is the substrate-recognition subunit of a CRL5 (Cullin5–ElonginBC–Rbx2) E3 ubiquitin ligase that uses its SH2 domain to bind phosphotyrosine degrons on activated cytokine and growth-factor receptors and direct them for K48-linked ubiquitination and proteasomal degradation, thereby acting as a negative-feedback brake on growth-hormone and related signaling [#19, #13, #21]. The complex was biophysically reconstituted as a monomeric SOCS2–ElonginBC–Cullin5–Rbx2 assembly that engages substrate via phosphorylated receptor peptides, and the SOCS-box motif that recruits Elongin B/C is essential for all of its inhibitory and ligase activity [#19, #5, #13]. Structurally, the SH2 domain captures pTyr peptides from substrates such as GHR and EpoR in an extended conformation, with substrate-specific EF-loop conformations and an allosteric exosite that stabilizes the domain and tightens phosphopeptide binding [#24, #26]. Its principal physiological role is degradation of the growth hormone receptor at phospho-Tyr487, limiting GH/STAT5b-driven somatic and mammary growth — loss of SOCS2 elevates GHR and prolongs STAT5 signaling in a STAT5b-dependent manner [#13, #21, #4, #9]. SOCS2 extends this activity to additional receptors and non-receptor substrates, recognizing FLT3 and the cystine transporter SLC7A11 (promoting ferroptosis) for ubiquitin-dependent degradation, and targeting the kinase NDR1/STK38 and SOCS1/SOCS3 [#16, #27, #22, #7]. Its own abundance is tuned transcriptionally — induced downstream of STAT5 and AhR — post-transcriptionally by METTL3/YTHDF2-mediated m6A decay of its mRNA, and post-translationally by the E3 ligase KIAA0317 [#15, #23, #25]. In immune cells SOCS2 acts as an anti-inflammatory regulator: it is induced by lipoxin A4/AhR signaling, restrains Th2 and iTreg responses and dendritic-cell inflammatory output, and limits NF-κB activation [#8, #14, #18, #22].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established SOCS2 as a physical partner of an activated growth-factor receptor, the first clue that it docks onto receptor signaling complexes.\",\n      \"evidence\": \"Yeast two-hybrid plus reciprocal Co-IP/GST-pulldown against the IGF-IR cytoplasmic domain\",\n      \"pmids\": [\"9727029\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define the phosphotyrosine degron bound\", \"No functional consequence of the interaction shown\", \"Distinguished SOCS2 from SOCS1/SOCS3 only by binding, not mechanism\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolved the paradox that SOCS2 enhances rather than suppresses growth and placed it as a GHR-binding negative regulator acting upstream of STAT5b.\",\n      \"evidence\": \"Transgenic and SOCS2/STAT5b double-knockout mouse genetics with GHR phosphopeptide binding mapping (pTyr595) and prolonged hepatocyte STAT5 phosphorylation\",\n      \"pmids\": [\"12208853\", \"12040024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of GHR downregulation (degradation vs signaling block) not yet defined\", \"Biphasic dose-dependent growth phenotype unexplained\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed the SOCS-box is indispensable for inhibitory function and that SOCS2 can act through E3-ligase-type degradation of other SOCS proteins, foreshadowing its ligase identity.\",\n      \"evidence\": \"SOCS2-/- mice with exogenous GH, structure/function mutagenesis of GHR tyrosines and the SOCS-box, and proteasome/elongin BC-dependent SOCS3 degradation assays\",\n      \"pmids\": [\"15690087\", \"16199887\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct demonstration of intrinsic ubiquitin ligase activity still lacking\", \"Which substrates degraded in vivo unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Expanded SOCS2 into immune and developmental physiology — anti-inflammatory control downstream of lipoxin A4/AhR and regulation of prolactin-driven mammary morphogenesis.\",\n      \"evidence\": \"SOCS2-/- mouse infection and DC stimulation models; Socs2/PrlR epistatic mouse crosses with pSTAT5 readouts; reports of non-GH JunB stabilization\",\n      \"pmids\": [\"16415877\", \"16469767\", \"16419040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether immune phenotypes reflect receptor degradation or signaling competition not separated\", \"Direct substrates in immune cells not identified at this stage\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated direct intrinsic ubiquitin ligase activity, establishing SOCS2 as an E3 that ubiquitinates GHR for proteasomal degradation and assigning distinct GHR tyrosines to binding vs degradation.\",\n      \"evidence\": \"In vitro ubiquitin ligase assays, mutational mapping (Tyr487 for degradation), SOCS2-/- liver GHR levels, proteasome inhibition; parallel T-cell knockout studies of Th2 control\",\n      \"pmids\": [\"21980433\", \"21646394\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full ligase complex composition and stoichiometry not yet defined\", \"Substrate repertoire beyond GHR incomplete\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the molecular machine by reconstituting the full CRL5(SOCS2) complex and measuring its internal interaction affinities.\",\n      \"evidence\": \"In vitro reconstitution of SOCS2–ElonginBC–Cullin5–Rbx2, phospho-GHR peptide pulldown, SEC-MALS, native MS and ITC\",\n      \"pmids\": [\"25505247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not provide atomic structure of substrate engagement\", \"Catalytic cycle and neddylation dependence not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided structural and disease-relevant detail of substrate recognition, linking a GHR variant that disrupts SOCS2 binding to impaired receptor degradation and prolonged GH signaling.\",\n      \"evidence\": \"NMR comparison of GHR P495T, TIRF/surface receptor imaging, mutagenesis; proteomic identification of NDR1/STK38 as a K48-ubiquitinated substrate with SOCS2-/- colitis model\",\n      \"pmids\": [\"28967904\", \"28216640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GHR P495T causes a human growth phenotype not established here\", \"Breadth of non-receptor substrate degron preferences unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Delivered atomic-resolution substrate recognition and revealed dual regulation of SOCS2 abundance by m6A mRNA decay and by a counteracting E3 ligase.\",\n      \"evidence\": \"Co-crystal structures of SOCS2-EloBC with GHR(pY595) and EpoR(pY426); METTL3/YTHDF2 m6A-seq/meRIP in HCC; KIAA0317 KO mice and inhibitor (BC-1365) in lung inflammation\",\n      \"pmids\": [\"31182716\", \"29171881\", \"31578312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for substrate selectivity beyond pY pocket only partially explained by EF-loop\", \"Crosstalk between transcriptional, m6A, and proteostatic control not integrated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended SOCS2 substrate scope to the cystine transporter SLC7A11, coupling its ligase activity to ferroptosis and radiosensitization in cancer.\",\n      \"evidence\": \"Co-IP, domain mutagenesis (SH2 N-terminal recognition; SOCS-BOX L162/C166 for elongin BC), K48 ubiquitination assays, ferroptosis readouts and xenografts\",\n      \"pmids\": [\"35995846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of N-terminal (non-pTyr) substrate recognition unclear\", \"In vivo contribution to tumor ferroptosis vs other pathways not isolated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Validated SOCS2 as a druggable target through structure-guided allosteric and covalent ligands that modulate phosphopeptide binding and block substrate recruitment.\",\n      \"evidence\": \"Crystal structure of an exosite-binding helical peptide enhancing binding; covalent Cys111 inhibitor MN551/prodrug MN714 with co-crystal, 19F NMR and cellular target engagement\",\n      \"pmids\": [\"34857742\", \"37816714\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous ligand or physiological role of the exosite unknown\", \"Cellular and in vivo efficacy of covalent inhibitors not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the full substrate repertoire and degron rules of CRL5(SOCS2) are decoded in different tissues, and how its multilayer regulation is coordinated, remains open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unbiased proteome-wide degradation atlas across cell types\", \"Integration of STAT5/AhR transcription, m6A decay, and KIAA0317 turnover into a quantitative regulatory model lacking\", \"Whether reported non-degradative signaling roles (e.g., EGFR/Src in neurons) reflect a distinct mechanism unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [13, 19, 22, 27]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [13, 16, 22, 27]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 24]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 7, 15]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [19, 21, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [19, 13]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [16, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [13, 19, 22, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 4, 5, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 14, 18, 22]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"complexes\": [\"CRL5(SOCS2) (SOCS2–ElonginBC–Cullin5–Rbx2) E3 ubiquitin ligase\"],\n    \"partners\": [\"GHR\", \"ElonginB\", \"ElonginC\", \"CUL5\", \"FLT3\", \"SLC7A11\", \"STK38\", \"IGF1R\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}